Studies from University Hospital Sart Tilman in the Area of Breast Cancer Described (Neoadjuvant Nivolumab Plus Palbociclib Plus Anastrozole for Oestrogen Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Primary Breast ...)

Source :: Immunotherapy Weekly. December 6, 2023, 608
Publication Year :: 2023
Abstract: 2023 DEC 6 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Research findings on Oncology - Breast Cancer are discussed in a new report. According to [...]

Subjects :: Bristol-Myers Squibb Co.
Care and treatment
Research
Palbociclib -- Research
Anastrozole -- Research
Cancer research
Nivolumab -- Research
Immunotherapy -- Research
Estrogens -- Research
Epidermal growth factors -- Research
Pharmaceutical industry -- Research
Breast cancer -- Research -- Care and treatment
Oncology, Experimental
Estrogen -- Research
Cancer -- Research
Epidermal growth factor -- Research

Tools